Our 2026 S&P 500 Index target is 8,000 for 2026, assuming a 23x multiple of 2027 estimated S&P earnings of 348. Read more ...

Mike Wolanin | The Republic Phil Powell, executive director of the Indiana Business Research Center and clinical associate professor of business economics and public policy at the Kelley School of ...

LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in ...

CALGARY, AB, Dec. 3, 2025 /PRNewswire/ - Enbridge Inc. (Enbridge or the Company) (TSX: ENB) (NYSE: ENB) announced today its ...

People are getting more pessimistic about their own financial outlook for the year ahead, according to the latest Survey of Consumer Expectations from the Federal Reserve Bank of New York. More than a ...

Private market funds are finding creative but little-regulated quick fixes to avoid defaults under tighter monetary policy. Those strategies make it tough to assess the underlying quality of the ...

Tariffs, trends & turbulence—Gus Faucher joins Economic Outlook this week. This week on Economic Outlook, we’re joined by PNC Chief Economist Gus Faucher for an in-depth conversation on the current ...

CivicScience engages directly with consumers, collecting over one million survey responses daily, to turn real-time insights into high-performing advertising campaigns. See how leading brands use ...

Exploring Mno-Bmadsen’s impact on economic growth and sustainability for the Pokagon Mno-Bmadsen, the non-gaming investment arm of the Pokagon Band of Potawatomi, is driving economic growth and ...

This analysis is by Bloomberg Intelligence Senior Analyst Alison Williams and Analyst Neil Sipes. It appeared first on the Bloomberg Terminal. Asset and wealth managers’ revenue outlook is supported ...

Join the Puget Sound Business Journal for the 2026 Economic Outlook, where local executives and industry leaders will gather ...

U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025. Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe ...